Impact of anti-rheumatic treatment on the individual components of the American College of Rheumatology (ACR) composite score in patients with rheumatoid arthritis: real-world data
Authors' conclusion
In this real-world practice, physician-reported measures contribute slightly more to overall ACR20/50/70 responses. Pain was the most important factor in achieving an ACR50 TOFA users, possibly reflecting the different effects of JAKi on pain.
Study context
- Population
- Rheumatoid arthritis (RA) patients with CDAI >10 at treatment start, Ontario Best Practices Research Initiative (OBRI) and RHUMADATA registries
- Participants
- 669 patients
- Exposure
- csDMARDs vs TNF inhibitors (TNFi) vs tofacitinib
- csDMARDn = 157
- TNFin = 252
- Tofacitinib (TOFA)n = 260
- Outcome
- Proportions achieving ACR20/50/70 responses, ≥20/50/70% improvements and mean percentage improvement in individual ACR components
- Follow-up
- Month 6
Methodological detailspooled data from two registries (OBRI and RHUMADATA), adjusted for potential confounders
- Pooled data from two registries (OBRI and RHUMADATA)
- Adjusted for potential confounders
Main finding
As reported in the abstract
Improvement in individual ACR components
Among ACR20/50/70 responders, mean % improvement in primary components
more than 80%
Among ACR20/50/70 responders, mean % improvement in secondary components
30% to 80%
Observational data: associations, not effects.
Further findings
≥50% improvement in pain (adjusted) · Month 6
- Significantly lower proportion with TNFi vs TOFA after adjusting
Original publication
Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data. Clin Exp Rheumatol. Published 5 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →